Dexketoprofen is commonly used across domains where short-term symptom management is appropriate for physical discomfort and inflammation. Its primary therapeutic benefit may be its supportive role during acute episodes of discomfort. It is applied in addressing symptomatic pain of mild to moderate intensity.

The medication is commonly used across conditions presenting with acute episodes, including symptoms related to physical discomfort like musculoskeletal pain (such as sprains and strains), dental pain, and dysmenorrhea. It may also be applied in addressing acute discomfort like renal colic.

“The medication helps address symptom clusters that may become intense or disruptive, providing supportive relief when symptoms interfere with routine activities.”

Relief of Acute Musculoskeletal and Traumatic Pain

This domain covers acute discomfort and swelling associated with sprains and muscle strains. The medication is applied in situations where symptoms are related to inflammatory or irritative states, assisting with easing the overall burden of movement-related pain and stiffness.

Symptomatic Management of Post-Surgical Discomfort

Dexketoprofen is relevant in clinical settings for controlling postoperative pain. Applied during phases when symptoms become more noticeable, it offers symptomatic relief that may help patients cope more steadily during difficult episodes.

Quick Fact: Relief for Acute Discomfort

Quick Fact: Relief for Acute Discomfort in the form of pain and inflammation, supporting the patient during time-limited symptomatic episodes.

Regulatory References

1. Summary of Product Characteristics from the Irish Health Products Regulatory Authority (HPRA)

Eligibility Map: Who Can and Cannot Use Stadium (Dexketoprofen)

This medicine is primarily intended for use in adults (typically 18 years and older). Official regulatory information strictly defines which populations should not take this medicine (Contraindications) or for whom use is restricted.

Populations That Must Not Use Dexketoprofen

Use is contraindicated (absolutely prohibited) in patients with:

• Known allergy or hypersensitivity to dexketoprofen, aspirin, or other NSAIDs.
• Active or recurrent stomach/intestinal ulceration or bleeding.
• Severe conditions like severe heart failure, severe renal impairment (kidney function), or severe hepatic impairment (liver function).
• Any active bleeding disorder or a history of severe gastrointestinal bleeding related to previous NSAID use.
• The third trimester of pregnancy or during breast-feeding (lactation).

Populations Requiring Special Consideration

• Children and Adolescents: Use is not recommended because safety and efficacy have not been established.
• Elderly Patients: Treatment must begin at the lowest possible dose due to an increased risk of severe adverse effects.
• Mild to Moderate Organ Impairment: Patients with mild to moderate hepatic or renal impairment may require a reduced starting dose and close medical supervision.
• Women Attempting to Conceive: The medicine is not recommended as it may temporarily impair female fertility.

Interactions with other medicines and products

The official regulatory profile for Dexketoprofen interactions classifies co-administration into specific risk categories based on documented outcomes. Co-administration is formally contraindicated with several substances due to explicit, documented risks. These prohibited combinations include other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), high-dose Acetylsalicylic Acid, therapeutic doses of Anticoagulants (such as Warfarin), Lithium, and Methotrexate when administered at high doses (equal to or exceeding 15 mg/ week).

Other interactions are categorized as requiring caution due to altered exposure or pharmacodynamic risk. Co-administration with agents that affect renal function, such as Diuretics, ACE Inhibitors, and ARBs, is officially noted for an increased risk of nephrotoxicity. The plasma concentration and potential toxicity of Lithium and low-dose Methotrexate may be elevated due to a reduction in their renal clearance. Furthermore, combining this medicine with Oral Corticosteroids, SSRIs, or Anti-platelet Agents increases the documented pharmacodynamic risk of gastrointestinal bleeding.

Regarding non-medicinal substances, the official label notes that concurrent consumption of alcohol increases the risk of gastrointestinal toxicity. For administration timing, food intake is documented to reduce the absorption rate of Dexketoprofen; therefore, the medicine is required to be taken at least 30 minutes before meals. Caution is also specifically noted for elderly patients, who have an increased vulnerability to intensified interaction effects.

Molecular Blockade of Cyclooxygenase (COX) Enzymes

The core biological action of Dexketoprofen is the non-selective inhibition of Cyclooxygenase ( COX-1 and COX-2) enzymes. This molecular blockade cuts off the beginning of the arachidonic acid cascade, preventing the synthesis of key eicosanoid mediators, such as Prostaglandin E2 ( PGE2).

---

Modulation of Nociceptive and Inflammatory Signaling

By suppressing PGE2 production, the drug directly alters nociceptive signaling and attenuates the inflammatory cascade activity. This mechanism operates both peripherally (reducing sensitization of pain receptors at injury sites) and centrally (dampening signal amplification in the spinal cord), which leads to the resultant physiological modulation of nociceptive and inflammatory processes.

---

️ Mechanism-Dependent Kinetics Influencing Physiological Onset

The drug’s formulation as the highly soluble trometamol salt ensures ultra-rapid absorption of the pharmacologically active S-(+)-enantiomer into the system. This chemical characteristic allows the molecule to quickly reach and inhibit the COX targets, resulting in a molecular blockade that directly translates into the observed kinetics of the PGE2 suppression effect.

Dexketoprofen is administered through oral and parenteral routes, defining its utility in different clinical scenarios. The oral form is available as 25 mg film-coated tablets or granules for solution, while the parenteral form is a 50 mg injectable solution used for either intravenous (IV) or intramuscular (IM) injection.

For oral administration, the standard recognized dosing regimen is 12.5 mg every 4 to 6 hours or 25 mg every 8 hours, with the total daily dose strictly limited to 75 mg. To achieve the most rapid absorption, the oral tablet should be swallowed with fluid at least 30 minutes before a meal.

The parenteral route utilizes a 50 mg dose administered every 8 to 12 hours, ensuring a minimum interval of 6 hours between each application. The maximum total daily dose for the injectable form is 150 mg. This route is restricted to short-term use, with injectable treatment limited to a maximum of two days, after which a switch to the oral form is required when possible.

Special dosing adjustments apply for specific populations. For older adults (the elderly) and individuals with mild renal or mild to moderate hepatic impairment, the initial total daily dose is reduced and should not exceed 50 mg. The use of Dexketoprofen in the pediatric population is generally not recommended as specific dose ranges are not established.

Research Evidence / Overview of Studies for Stadium (Dexketoprofen)

This overview summarizes the type of research that has been conducted to examine Dexketoprofen, focusing only on the study designs, the outcomes that were monitored, and areas where evidence is still emerging. Research described is used in exploring how symptoms change over time in acute pain situations.

---

Research Evidence for Acute Pain Management

The foundational research for this medicine consists primarily of Randomized Controlled Trials (RCTs) and scientific reviews that was studied for short-term, acute physical discomfort. These studies compare the medicine to a placebo (a sugar pill) or to other established pain relievers, and they focus on outcomes related to physical discomfort and outcomes describing episodic or acute changes. The evidence contributes to the broader evidence landscape of short-term symptom patterns.

Evidence for Use in Post-Surgical Pain

This area of research was evaluated in numerous short-term, well-designed RCTs and subsequent analyses, which studied the medicine's administration immediately following procedures like dental extractions or orthopedic surgery. These studies monitored outcomes related to symptom intensity or variability, focusing on how patients reported their experience. Research examined measures of patient-reported outcomes describing perceived discomfort, the total amount of pain reported, and the time until patients noticed a change in symptoms. Studies also explored whether the use of Dexketoprofen, particularly the injectable form, was associated with a change in the amount of other pain medication recorded, such as opioids, following the procedure.

Findings describe patterns observed in these studies where pain intensity measurements were monitored for changes during the defined short-term follow-up period. Across multiple studies, reported pain intensity difference measurements were examined relative to placebo or active comparators. However, follow-up durations were limited in these post-surgical studies. There is limited information for long-term outcomes, as the research focuses strictly on the few days required for initial symptom monitoring from the acute episode. Data are still emerging regarding its role in long-term functional status after surgery.

---

Duration of Research and Long-Term Follow-up

The vast majority of research that has evaluated the medicine was conducted during periods of increased symptom activity and focused on short-term symptom changes over defined time intervals. This means that the research provides context but not individual predictions about long-term use. Currently, there is limited information for long-term outcomes or how the observed short-term changes compare to extended use. The available studies and the findings reported reflect the specific conditions under which they were conducted.

---

What Remains Uncertain in the Study Landscape

While research helps show what has been observed so far in acute settings, several areas of uncertainty and limitation have been noted in the evidence landscape:

• Follow-up durations were limited across many key trials, leaving long-term effects not fully established.
• Comparative evidence is lacking for some indications, meaning direct head-to-head research with all other available pain treatments is not always available.
• The research does not determine whether an individual will respond similarly to the group patterns observed in studies.
• The overall body of evidence is the largest volume of evidence for acute pain models, and the findings cannot be generalized to the management of chronic, long-lasting conditions.

Key Studies & References

1. Summary of Product Characteristics - Keral (Dexketoprofen trometamol)
2. Dexketoprofen trometamol for acute pain: a systematic review and meta-analysis of randomized controlled trials

Common questions about Stadium (Dexketoprofen) (FAQ)

Q: Is Stadium (Dexketoprofen) considered a strong painkiller?

According to official regulatory sources, Dexketoprofen is indicated for the symptomatic treatment of pain that is classified as mild to moderate in intensity. The active ingredient itself is officially described as a potent Nonsteroidal Anti-inflammatory Drug (NSAID). This classification indicates its strength relative to its pharmacological class and the level of pain it is intended to address.

Q: Are there any major diet restrictions while taking Dexketoprofen?

Regulatory information highlights two important considerations regarding consumption. Concurrent consumption of alcohol is noted to increase the risk of gastrointestinal toxicity. Separately, official documents indicate that taking the medicine with food may reduce the rate at which the active ingredient is absorbed into the body.

Q: Is it true that Dexketoprofen acts faster than some other common pain relievers?

The drug's unique formulation, which uses the highly soluble trometamol salt, is designed to facilitate a rapid onset of action. Clinical research has included comparisons of its efficacy and time-to-onset against other established pain relievers used for acute conditions.

Q: Can Dexketoprofen cause drowsiness or affect driving?

Official product information states that this medicine may cause certain side effects such as dizziness, somnolence (drowsiness), or visual disturbances. Official labeling indicates that these effects carry a risk that may affect the ability to drive or operate machinery.

Q: Does Dexketoprofen affect blood clotting?

As a non-selective NSAID, Dexketoprofen is described in regulatory documents as having the ability to inhibit platelet aggregation, which may prolong bleeding time. This effect is a common pharmacological property of this class of medicine and is due to the inhibition of prostaglandin synthesis.

Q: What are the signs of an allergic reaction to Stadium (Dexketoprofen)?

Official patient information reports that signs of an allergic reaction may include breathing problems, swelling of the face and neck region (known as angioedema), or an itchy skin rash. If signs of a severe allergic reaction occur, this is recognized as an emergency requiring urgent medical attention.

Q: Can Dexketoprofen interact with common over-the-counter cold medicines?

Official patient warnings note that taking Dexketoprofen with any other anti-inflammatory painkiller (NSAID) is not recommended. It is noted that many over-the-counter cold and flu remedies may contain other NSAIDs, presenting an interaction risk.

Q: Is the mechanism of action for Dexketoprofen different from other NSAIDs?

The core way the medicine works is similar to many other NSAIDs: it inhibits Cyclooxygenase (COX) enzymes. Its unique characteristic is its composition as the single, pharmacologically active S-(+)-enantiomer combined with the trometamol salt, which is chemically recognized for its rapid absorption rate.

Q: Is there a maximum number of days I can take Dexketoprofen continuously?

The injectable form of the medicine is restricted to short-term use, with a maximum limit of two consecutive days of treatment. While the oral form is not intended for long-term or chronic use, its administration is generally limited to the symptomatic period as described in regulatory documents.

Q: Can Dexketoprofen be used for treating headaches?

Dexketoprofen is indicated for the symptomatic treatment of pain classified as mild to moderate in intensity. While headaches are not always specifically listed as an indication in official therapeutic documents, the medicine's general purpose is acute pain relief.

Q: Can Dexketoprofen be taken with paracetamol (acetaminophen)?

Official drug labeling does not list paracetamol (acetaminophen) as a formal contraindication in its specific drug interactions section. This combination is often monitored by practitioners and mentioned in clinical literature within the context of established multimodal pain management settings.

Q: Is there a risk of becoming dependent on Dexketoprofen?

Dexketoprofen is pharmacologically classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). According to governmental drug classification systems, NSAIDs are not listed as controlled substances.

Q: What should I do if I forget to take a dose of Dexketoprofen?

Official patient information states that a double dose should not be taken to compensate for a forgotten one. Patients are generally directed to consult the specific administration schedule provided in the prescribing information for guidance on how to resume the treatment.

Q: Can Dexketoprofen be taken by people with asthma?

This medicine is contraindicated, meaning absolutely prohibited, in patients who have a history of asthma, urticaria (hives), or other allergic-type reactions that occurred after taking aspirin or other NSAIDs. This constraint is due to the potential for severe reactions like bronchospasm.

Q: Is Dexketoprofen mentioned in clinical guidelines for acute pain?

The large volume of research evidence for Dexketoprofen is primarily focused on its use within acute pain models, such as post-surgical discomfort. Furthermore, the combination of NSAIDs, which includes this medicine, is mentioned in certain established clinical guidelines for multimodal pain management strategies.

Q: Can Dexketoprofen be used for menstrual pain?

According to the official therapeutic indications listed in regulatory documents, the medicine is indicated for the symptomatic treatment of pain of mild to moderate intensity, which includes dysmenorrhoea (menstrual pain).

How to Store and Dispose of Stadium (Dexketoprofen)

Official regulatory requirements strictly define the storage and disposal of Dexketoprofen to maintain its stability.

Storage Requirements

Storage Component	Official Requirement
Container & Protection	Must be stored in the original outer carton to protect the product from light.
Temperature (PVC-Alu Blister)	Do not store above 30 C.
Temperature (Other Blisters)	No special temperature storage conditions are required for Aclar-Aluminium or Aluminium-Aluminium blister packs.
Stability Link	The shelf-life of the product is dependent on the packaging material and its associated temperature constraint.

Disposal Instructions

Any unused or expired Dexketoprofen product, along with any waste material, must be disposed of in accordance with local requirements. This instruction mandates following the established local system for the collection and disposal of pharmaceutical waste.